{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-22-002162","form_type":"8-K","ticker":"PMDI","cik":"0000806517","company_name":"PSYCHEMEDICS CORP","filed_at":"2022-03-29T23:59:59+00:00","discovered_at":"2026-05-14T18:04:09.840297+00:00","generated_at":"2026-06-26T15:29:08.827086+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Psychemedics FY2021 revenue up 17% to $24.9M; net loss narrows to $0.7M from $3.9M","bullets":["Full-year revenue $24.9M (+17% YoY); net loss $0.7M ($0.12/diluted) vs $3.9M ($0.70) loss in 2020.","Q4 revenue $6.4M (+21% YoY) but Q4 net loss widened to $1.6M ($0.29/diluted) from $0.5M ($0.10).","PPP loan of $2.2M forgiven; $2.6M employee retention credits recognized; $3.3M in legal settlement charges.","Resumed quarterly dividend in Q4 2021 after pandemic suspension; board to evaluate future dividends.","Exploring strategic alternatives; year-end cash $2.0M, working capital $4.5M, equipment debt $1.3M."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-22-002162","json":"https://secwatch.observer/filing/0001171843-22-002162.json","markdown":"https://secwatch.observer/filing/0001171843-22-002162.md","text":"https://secwatch.observer/filing/0001171843-22-002162.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/806517/000117184322002162/0001171843-22-002162-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/806517/000117184322002162/f8k_032922.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T15:29:08.827086+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}